Abstract
Parkinson’s disease (PD) is a neurological disorder that is commonly associated with motor system dysfunction. This is often demonstrated as functional deficits in movement, with fundamental symptoms such as bradykinesia (slowness of movement) and tremors. Non-motor features are also prevalent in its pathology through the degradation of specific neural regions and are prone to emerging during the prodromal stages of the disease. These neurological manifestations can exist as dysfunctions in the autonomic system or behavioural impairments in sleep, and progressive cognitive decline. This drives a growing interest for early identification of these neuropathologies, developing standardised practices to support a future for earlier interventions.
Current predictive measures towards cognitive decline are saturated with clinical assessments that lack accessibility and nuance in their purpose. These are often beneficial at predicting later stages of disease progression, leaving a gap for research towards early identification. Recent focus has shifted towards plasma biomarkers for their abilities to reflect pathological change, establishing a potential for early diagnosis of PD through the molecular properties of these biomarkers. A particular example resides in assessing the levels of small non-coding RNA species such as microRNAs (miRNAs), which have been found as biological targets that depict the pathology of PD.
This incentive to cultivate reliable biomarkers for PD forms the basis of this study, aiming to validate the expression levels of specific miRNAs (miR-142-3p, miR-151-3p, miR-191-5p, and miR-192-5p) chosen for their ability to provide the best predictive models for separating cognitively normal patients from those who decline cognitively (Guévremont et al., 2026). This study will aim to support the purpose of plasma miRNA levels in PD to predict the onset of neurological decline in non-motor-related features.
To assess the validity of these 4 miRNAs, RNA was extracted from 79 plasma samples provided by the New Zealand Parkinson’s Progression Programme (NZP3) from 40 PD individuals. TaqMan™ Primers, MicroRNA Assays and RT q-PCRs were used to quantify miRNA to evaluate changes in expression with subsequent statistical analyses. Cognitive decline in PD was monitored in two longitudinal cohorts: 24 individuals progressed from Parkinson’s with Normal Cognition (PDN) to Parkinson’s with Mild-Cognitive Impairment (PDN → PD-MCI), and 16 progressed from Parkinson’s with Mild-Cognitive Impairment to Parkinson’s with Dementia (PD-MCI → PD-D). One individual traversed through all designations, sharing the same PD-MCI sample for each cohort.
Results exhibit significance in both expressions of miR-151-3p and miR-192-5p in their respective longitudinal cohorts. Significant upregulation was found in the PDN → PD-MCI cohort for miR-151-3p (p = 0.008). Significant downregulation was seen in both cohorts for miR-192-5p, with PDN → PD-MCI (p = 0.031) and PD-MCI → PD-D) (p = 0.001). The classification of PD patients will also supplement opportunities to procure stronger insight into disease-specific mechanisms, enhancing translational data for counteractive strategies. Additionally, accessibility to these predictive measures can support marginalised groups affected by PD, acknowledging the disparities faced by Māori in the healthcare system by incorporating cultural perspectives that uplift underrepresented communities in health.